220
Participants
Start Date
December 30, 2022
Primary Completion Date
April 30, 2025
Study Completion Date
February 28, 2026
SHR-A1921;
Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion
Tianjin Medical University Cancer Institute& Hospital, Tianjin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
INDUSTRY